Johnson & Johnson (JNJ) on Thursday announced that the U.S. Food and Drug Administration (FDA) has approved Caplyta as an add-on therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The approval was supported by two Phase 3 studies that met their primary endpoints, showing statistically significant and clinically meaningful improvements in depression symptoms compared with an oral antidepressant plus placebo.
Caplyta is already approved for bipolar I and II depression as well as for schizophrenia in adults.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.